Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non–small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison

After MAIC and subsequent immunotherapy adjustments, pembrolizumab plus chemotherapy showed improved overall survival and progression-free survival versus cemiplimab plus chemotherapy in both non-squamous and squamous metastatic NSCLC at modest incremental cost.